UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________________________
Form 10-Q
__________________________________________________________
| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||
FOR THE QUARTERLY PERIOD ENDED June 30, 2022
or
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||
FOR THE TRANSITION PERIOD FROM _______ TO _______
Commission File Number: 1-10864
__________________________________________________________
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
__________________________________________________________
| Delaware | 41-1321939 | ||||||||||
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | ||||||||||
| UnitedHealth Group Center | 55343 | ||||||||||
| 9900 Bren Road East | |||||||||||
Minnetonka, | Minnesota | ||||||||||
| (Address of principal executive offices) | (Zip Code) | ||||||||||
(952) 936-1300
(Registrant’s telephone number, including area code)
_________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Common Stock, $.01 par value | UNH | New York Stock Exchange | ||||||||||||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act
| Large accelerated filer | ☒ | Accelerated filer | ☐ | Non-accelerated filer | ☐ | ||||||||||||||||||
| Smaller reporting company | ☐ | Emerging growth company | ☐ | ||||||||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of July 29, 2022, there were 935,382,710 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.
UNITEDHEALTH GROUP
Table of Contents
| Page | ||||||||||||||
PART I
ITEM 1. FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
| (in millions, except per share data) | June 30, 2022 | December 31, 2021 | ||||||||||||
| Assets | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash and cash equivalents | $ | 24,612 | $ | 21,375 | ||||||||||
| Short-term investments | 3,352 | 2,532 | ||||||||||||
| Accounts receivable, net | 18,718 | 14,216 | ||||||||||||
| Other current receivables, net | 12,439 | 13,866 | ||||||||||||
| Assets under management | 4,017 | 4,449 | ||||||||||||
| Prepaid expenses and other current assets | 5,218 | 5,320 | ||||||||||||
| Total current assets | 68,356 | 61,758 | ||||||||||||
| Long-term investments | 42,427 | 43,114 | ||||||||||||
Property, equipment and capitalized software, net | 9,421 | 8,969 | ||||||||||||
| Goodwill | 84,159 | 75,795 | ||||||||||||
| Other intangible assets, net | 11,285 | 10,044 | ||||||||||||
| Other assets | 14,524 | 12,526 | ||||||||||||
| Total assets | $ | 230,172 | $ | 212,206 | ||||||||||
| Liabilities, redeemable noncontrolling interests and equity | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Medical costs payable | $ | 28,978 | $ | 24,483 | ||||||||||
| Accounts payable and accrued liabilities | 25,145 | 24,643 | ||||||||||||
| Short-term borrowings and current maturities of long-term debt | 5,592 | 3,620 | ||||||||||||
| Unearned revenues | 2,212 | 2,571 | ||||||||||||
| Other current liabilities | 26,771 | 22,975 | ||||||||||||
| Total current liabilities | 88,698 | 78,292 | ||||||||||||
| Long-term debt, less current maturities | 45,799 | 42,383 | ||||||||||||
| Deferred income taxes | 2,581 | 3,265 | ||||||||||||
| Other liabilities | 11,967 | 11,787 | ||||||||||||
| Total liabilities | 149,045 | 135,727 | ||||||||||||
| Commitments and contingencies (Note 7) | ||||||||||||||
| Redeemable noncontrolling interests | 4,922 | 1,434 | ||||||||||||
| Equity: | ||||||||||||||
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding | — | — | ||||||||||||
Common stock, $0.01 par value - 3,000 shares authorized; 935 and 941 issued and outstanding | 10 | 10 | ||||||||||||
| Retained earnings | 80,540 | 77,134 | ||||||||||||
| Accumulated other comprehensive loss | (7,730) | (5,384) | ||||||||||||
Nonredeemable noncontrolling interests | 3,385 | 3,285 | ||||||||||||
| Total equity | 76,205 | 75,045 | ||||||||||||
| Total liabilities, redeemable noncontrolling interests and equity | $ | 230,172 | $ | 212,206 | ||||||||||
1
UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||
| (in millions, except per share data) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
| Revenues: | ||||||||||||||||||||||||||
| Premiums | $ | 63,896 | $ | 56,233 | $ | 127,966 | $ | 111,719 | ||||||||||||||||||
| Products | 9,496 | 8,433 | 18,836 | 16,773 | ||||||||||||||||||||||
| Services | 6,645 | 6,099 | 13,017 | 12,017 | ||||||||||||||||||||||
| Investment and other income | 295 | 556 | 662 | 1,008 | ||||||||||||||||||||||
| Total revenues | 80,332 | 71,321 | 160,481 | 141,517 | ||||||||||||||||||||||
| Operating costs: | ||||||||||||||||||||||||||
| Medical costs | 52,093 | 46,546 | 104,616 | 91,450 | ||||||||||||||||||||||
| Operating costs | 11,709 | 10,359 | 23,110 | 20,582 | ||||||||||||||||||||||
| Cost of products sold | 8,596 | 7,660 | 17,083 | 15,232 | ||||||||||||||||||||||
| Depreciation and amortization | 802 | 778 | 1,590 | 1,536 | ||||||||||||||||||||||
| Total operating costs | 73,200 | 65,343 | 146,399 | 128,800 | ||||||||||||||||||||||
| Earnings from operations | 7,132 | 5,978 | 14,082 | 12,717 | ||||||||||||||||||||||
| Interest expense | (467) | (410) | (900) | (807) | ||||||||||||||||||||||
| Earnings before income taxes | 6,665 | 5,568 | 13,182 | 11,910 | ||||||||||||||||||||||
| Provision for income taxes | (1,466) | (1,196) | (2,835) | (2,560) | ||||||||||||||||||||||
| Net earnings | 5,199 | 4,372 | 10,347 | 9,350 | ||||||||||||||||||||||
| Earnings attributable to noncontrolling interests | (129) | (106) | (250) | (222) | ||||||||||||||||||||||
| Net earnings attributable to UnitedHealth Group common shareholders | $ | 5,070 | $ | 4,266 | $ | 10,097 | $ | 9,128 | ||||||||||||||||||
| Earnings per share attributable to UnitedHealth Group common shareholders: | ||||||||||||||||||||||||||
| Basic | $ | 5.41 | $ | 4.52 | $ | 10.75 | $ | 9.66 | ||||||||||||||||||
| Diluted | $ | 5.34 | $ | 4.46 | $ | 10.61 | $ | 9.55 | ||||||||||||||||||
| Basic weighted-average number of common shares outstanding | 937 | 944 | 939 | 945 | ||||||||||||||||||||||
| Dilutive effect of common share equivalents | 13 | 12 | 13 | 11 | ||||||||||||||||||||||
| Diluted weighted-average number of common shares outstanding | 950 | 956 | 952 | 956 | ||||||||||||||||||||||
| Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents | 3 | 1 | 3 | 2 | ||||||||||||||||||||||
2
UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||
| (in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
| Net earnings | $ | 5,199 | $ | 4,372 | $ | 10,347 | $ | 9,350 | ||||||||||||||||||
| Other comprehensive (loss) income: | ||||||||||||||||||||||||||
| Gross unrealized (losses) gains on investment securities during the period | (1,331) | 251 | (3,354) | (513) | ||||||||||||||||||||||
| Income tax effect | 304 | (58) | 769 | 116 | ||||||||||||||||||||||
| Total unrealized (losses) gains, net of tax | (1,027) | 193 | (2,585) | (397) | ||||||||||||||||||||||
| Gross reclassification adjustment for net realized gains included in net earnings | (1) | (9) | (4) | (16) | ||||||||||||||||||||||
| Income tax effect | — | 2 | 1 | 4 | ||||||||||||||||||||||
Total reclassification adjustment, net of tax | (1) | (7) | (3) | (12) | ||||||||||||||||||||||
| Total foreign currency translation (losses) gains | (676) | 554 | 242 | 137 | ||||||||||||||||||||||
| Other comprehensive (loss) income | (1,704) | 740 | (2,346) | (272) | ||||||||||||||||||||||
| Comprehensive income | 3,495 | 5,112 | 8,001 | 9,078 | ||||||||||||||||||||||
| Comprehensive income attributable to noncontrolling interests | (129) | (106) | (250) | (222) | ||||||||||||||||||||||
Comprehensive income attributable to UnitedHealth Group common shareholders | $ | 3,366 | $ | 5,006 | $ | 7,751 | $ | 8,856 | ||||||||||||||||||
3
UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
| Common Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive (Loss) Income | Nonredeemable Noncontrolling Interests | Total Equity | |||||||||||||||||||||||||||||||||||||||||||||
| Three months ended June 30, (in millions) | Shares | Amount | Net Unrealized (Losses) Gains on Investments | Foreign Currency Translation (Losses) Gains | ||||||||||||||||||||||||||||||||||||||||||||||
| Balance at March 31, 2022 | 939 | $ | 10 | $ | — | $ | 78,782 | $ | (1,137) | $ | (4,889) | $ | 3,362 | $ | 76,128 | |||||||||||||||||||||||||||||||||||
Net earnings | 5,070 | 94 | 5,164 | |||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive loss | (1,028) | (676) | (1,704) | |||||||||||||||||||||||||||||||||||||||||||||||
Issuances of common stock, and related tax effects | 1 | — | 174 | 174 | ||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation | 194 | 194 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Common share repurchases | (5) | — | (733) | (1,767) | (2,500) | |||||||||||||||||||||||||||||||||||||||||||||
Cash dividends paid on common shares ($1.65 per share) | (1,545) | (1,545) | ||||||||||||||||||||||||||||||||||||||||||||||||
Redeemable noncontrolling interests fair value and other adjustments | 365 | 365 | ||||||||||||||||||||||||||||||||||||||||||||||||
Acquisition and other adjustments of nonredeemable noncontrolling interests | 12 | 12 | ||||||||||||||||||||||||||||||||||||||||||||||||
Distribution to nonredeemable noncontrolling interests | (83) | (83) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2022 | 935 | $ | 10 | $ | — | $ | 80,540 | $ | (2,165) | $ | (5,565) | $ | 3,385 | $ | 76,205 | |||||||||||||||||||||||||||||||||||
| Balance at March 31, 2021 | 944 | $ | 10 | $ | — | $ | 71,220 | $ | 741 | $ | (5,567) | $ | 2,909 | $ | 69,313 | |||||||||||||||||||||||||||||||||||
Net earnings | 4,266 | 88 | 4,354 | |||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income | 186 | 554 | 740 | |||||||||||||||||||||||||||||||||||||||||||||||
Issuances of common stock, and related tax effects | 2 | — | 292 | 292 | ||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation | 158 | 158 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Common share repurchases | (3) | — | (221) | (1,029) | (1,250) | |||||||||||||||||||||||||||||||||||||||||||||
Cash dividends paid on common shares ($1.45 per share) | (1,367) | (1,367) | ||||||||||||||||||||||||||||||||||||||||||||||||
Redeemable noncontrolling interests fair value and other adjustments | (229) | (229) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Acquisition and other adjustments of nonredeemable noncontrolling interests | 85 | 85 | ||||||||||||||||||||||||||||||||||||||||||||||||
Distribution to nonredeemable noncontrolling interests | (74) | (74) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2021 | 943 | $ | 10 | $ | — | $ | 73,090 | $ | 927 | $ | (5,013) | $ | 3,008 | $ | 72,022 | |||||||||||||||||||||||||||||||||||
4
UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
| Common Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Nonredeemable Noncontrolling Interests | Total Equity | |||||||||||||||||||||||||||||||||||||||||||||
| Six months ended June 30, (in millions) | Shares | Amount | Net Unrealized Gains (Losses) on Investments | Foreign Currency Translation (Losses) Gains | ||||||||||||||||||||||||||||||||||||||||||||||
| Balance at January 1, 2022 | 941 | $ | 10 | $ | — | $ | 77,134 | $ | 423 | $ | (5,807) | $ | 3,285 | $ | 75,045 | |||||||||||||||||||||||||||||||||||
Net earnings | 10,097 | 182 | 10,279 | |||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive (loss) income | (2,588) | 242 | (2,346) | |||||||||||||||||||||||||||||||||||||||||||||||
Issuances of common stock, and related tax effects | 4 | — | 507 | 507 | ||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation | 476 | 476 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Common share repurchases | (10) | — | (1,217) | (3,783) | (5,000) | |||||||||||||||||||||||||||||||||||||||||||||
Cash dividends paid on common shares ($3.10 per share) | (2,908) | (2,908) | ||||||||||||||||||||||||||||||||||||||||||||||||
Redeemable noncontrolling interests fair value and other adjustments | 234 | 234 | ||||||||||||||||||||||||||||||||||||||||||||||||
Acquisition and other adjustments of nonredeemable noncontrolling interests | 103 | 103 | ||||||||||||||||||||||||||||||||||||||||||||||||
Distribution to nonredeemable noncontrolling interests | (185) | (185) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2022 | 935 | $ | 10 | $ | — | $ | 80,540 | $ | (2,165) | $ | (5,565) | $ | 3,385 | $ | 76,205 | |||||||||||||||||||||||||||||||||||
| Balance at January 1, 2021 | 946 | $ | 10 | $ | — | $ | 69,295 | $ | 1,336 | $ | (5,150) | $ | 2,837 | $ | 68,328 | |||||||||||||||||||||||||||||||||||
Net earnings | 9,128 | 168 | 9,296 | |||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive (loss) income | (409) | 137 | (272) | |||||||||||||||||||||||||||||||||||||||||||||||
Issuances of common stock, and related tax effects | 5 | — | 548 | 548 | ||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation | 400 | 400 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Common share repurchases | (8) | — | (221) | (2,679) | (2,900) | |||||||||||||||||||||||||||||||||||||||||||||
Cash dividends paid on common shares ($2.70 per share) | (2,548) | (2,548) | ||||||||||||||||||||||||||||||||||||||||||||||||
Redeemable noncontrolling interests fair value and other adjustments | (727) | (106) | (833) | |||||||||||||||||||||||||||||||||||||||||||||||
| Acquisitions and other adjustments of nonredeemable noncontrolling interests | 151 | 151 | ||||||||||||||||||||||||||||||||||||||||||||||||
Distribution to nonredeemable noncontrolling interests | (148) | (148) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2021 | 943 | $ | 10 | $ | — | $ | 73,090 | $ | 927 | $ | (5,013) | $ | 3,008 | $ | 72,022 | |||||||||||||||||||||||||||||||||||
5
UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Six Months Ended June 30, | ||||||||||||||
| (in millions) | 2022 | 2021 | ||||||||||||
| Operating activities | ||||||||||||||
| Net earnings | $ | 10,347 | $ | 9,350 | ||||||||||
| Noncash items: | ||||||||||||||
| Depreciation and amortization | 1,590 | 1,536 | ||||||||||||
| Deferred income taxes | (15) | 327 | ||||||||||||
| Share-based compensation | 504 | 426 | ||||||||||||
| Other, net | 215 | (214) | ||||||||||||
Net change in other operating items, net of effects from acquisitions and changes in AARP balances: | ||||||||||||||
| Accounts receivable | (4,204) | (1,218) | ||||||||||||
| Other assets | (643) | (1,523) | ||||||||||||
| Medical costs payable | 4,029 | 3,086 | ||||||||||||
| Accounts payable and other liabilities | 807 | 298 | ||||||||||||
| Unearned revenues | (440) | (523) | ||||||||||||
| Cash flows from operating activities | 12,190 | 11,545 | ||||||||||||
| Investing activities | ||||||||||||||
| Purchases of investments | (8,903) | (8,847) | ||||||||||||
| Sales of investments | 2,348 | 1,408 | ||||||||||||
| Maturities of investments | 3,189 | 4,650 | ||||||||||||
| Cash paid for acquisitions, net of cash assumed | (7,150) | (4,642) | ||||||||||||
| Purchases of property, equipment and capitalized software | (1,212) | (1,130) | ||||||||||||
| Other, net | (532) | (648) | ||||||||||||
| Cash flows used for investing activities | (12,260) | (9,209) | ||||||||||||
| Financing activities | ||||||||||||||
| Common share repurchases | (5,000) | (2,900) | ||||||||||||
| Cash dividends paid | (2,908) | (2,548) | ||||||||||||
| Proceeds from common stock issuances | 756 | 764 | ||||||||||||
| Repayments of long-term debt | (1,100) | (1,900) | ||||||||||||
| Proceeds from (repayments of) short-term borrowings, net | 1,340 | (176) | ||||||||||||
| Proceeds from issuance of long-term debt | 5,922 | 6,934 | ||||||||||||
| Customer funds administered | 5,786 | 2,395 | ||||||||||||
| Purchases of redeemable noncontrolling interests | (97) | (1,338) | ||||||||||||
| Other, net | (1,449) | (662) | ||||||||||||
| Cash flows from financing activities | 3,250 | 569 | ||||||||||||
| Effect of exchange rate changes on cash and cash equivalents | 57 | 6 | ||||||||||||
| Increase in cash and cash equivalents | 3,237 | 2,911 | ||||||||||||
| Cash and cash equivalents, beginning of period | 21,375 | 16,921 | ||||||||||||
| Cash and cash equivalents, end of period | $ | 24,612 | $ | 19,832 | ||||||||||
6
UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1. Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary business platforms — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC (2021 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.
7
2. Investments
A summary of debt securities by major security type is as follows:
| (in millions) | Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | ||||||||||||||||||||||
| June 30, 2022 | ||||||||||||||||||||||||||
| Debt securities - available-for-sale: | ||||||||||||||||||||||||||
| U.S. government and agency obligations | $ | 3,808 | $ | 1 | $ | (209) | $ | 3,600 | ||||||||||||||||||
| State and municipal obligations | 7,725 | 25 | (381) | 7,369 | ||||||||||||||||||||||
| Corporate obligations | 22,080 | 5 | (1,515) | 20,570 | ||||||||||||||||||||||
| U.S. agency mortgage-backed securities | 6,275 | 2 | (537) | 5,740 | ||||||||||||||||||||||
| Non-U.S. agency mortgage-backed securities | 2,926 | — | (201) | 2,725 | ||||||||||||||||||||||
| Total debt securities - available-for-sale | 42,814 | 33 | (2,843) | 40,004 | ||||||||||||||||||||||
| Debt securities - held-to-maturity: | ||||||||||||||||||||||||||
| U.S. government and agency obligations | 544 | — | (11) | 533 | ||||||||||||||||||||||
| State and municipal obligations | 29 | — | (2) | 27 | ||||||||||||||||||||||
| Corporate obligations | 141 | — | — | 141 | ||||||||||||||||||||||
| Total debt securities - held-to-maturity | 714 | — | (13) | 701 | ||||||||||||||||||||||
| Total debt securities | $ | 43,528 | $ | 33 | $ | (2,856) | $ | 40,705 | ||||||||||||||||||
| December 31, 2021 | ||||||||||||||||||||||||||
| Debt securities - available-for-sale: | ||||||||||||||||||||||||||
| U.S. government and agency obligations | $ | 3,206 | $ | 23 | $ | (31) | $ | 3,198 | ||||||||||||||||||
| State and municipal obligations | 6,829 | 297 | (20) | 7,106 | ||||||||||||||||||||||
| Corporate obligations | 20,947 | 372 | (145) | 21,174 | ||||||||||||||||||||||
| U.S. agency mortgage-backed securities | 5,868 | 88 | (55) | 5,901 | ||||||||||||||||||||||
| Non-U.S. agency mortgage-backed securities | 2,819 | 42 | (23) | 2,838 | ||||||||||||||||||||||
| Total debt securities - available-for-sale | 39,669 | 822 | (274) | 40,217 | ||||||||||||||||||||||
| Debt securities - held-to-maturity: | ||||||||||||||||||||||||||
| U.S. government and agency obligations | 511 | 2 | (2) | 511 | ||||||||||||||||||||||
| State and municipal obligations | 30 | 2 | — | 32 | ||||||||||||||||||||||
| Corporate obligations | 100 | — | — | 100 | ||||||||||||||||||||||
| Total debt securities - held-to-maturity | 641 | 4 | (2) | 643 | ||||||||||||||||||||||
| Total debt securities | $ | 40,310 | $ | 826 | $ | (276) | $ | 40,860 | ||||||||||||||||||
The Company held $3.4 billion and $3.5 billion of equity securities as of June 30, 2022 and December 31, 2021, respectively. The Company’s investments in equity securities primarily consist of employee savings plan related investments, other venture investments and shares of Brazilian real denominated fixed-income funds with readily determinable fair values. Additionally, the Company’s investments included $1.7 billion and $1.3 billion of equity method investments in operating businesses in the health care sector as of June 30, 2022 and December 31, 2021, respectively. The allowance for credit losses on held-to-maturity securities at June 30, 2022 and December 31, 2021 was not material.
8
The amortized cost and fair value of debt securities as of June 30, 2022, by contractual maturity, were as follows:
| Available-for-Sale | Held-to-Maturity | |||||||||||||||||||||||||
| (in millions) | Amortized Cost | Fair Value | Amortized Cost | Fair Value | ||||||||||||||||||||||
| Due in one year or less | $ | 3,439 | $ | 3,422 | $ | 385 | $ | 381 | ||||||||||||||||||
| Due after one year through five years | 13,237 | 12,672 | 295 | 288 | ||||||||||||||||||||||
| Due after five years through ten years | 12,332 | 11,213 | 14 | 13 | ||||||||||||||||||||||
| Due after ten years | 4,605 | 4,232 | 20 | 19 | ||||||||||||||||||||||
| U.S. agency mortgage-backed securities | 6,275 | 5,740 | — | — | ||||||||||||||||||||||
| Non-U.S. agency mortgage-backed securities | 2,926 | 2,725 | — | — | ||||||||||||||||||||||
| Total debt securities | $ | 42,814 | $ | 40,004 | $ | 714 | $ | 701 | ||||||||||||||||||
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:
| Less Than 12 Months | 12 Months or Greater | Total | ||||||||||||||||||||||||||||||||||||
| (in millions) | Fair Value | Gross Unrealized Losses | Fair Value | Gross Unrealized Losses | Fair Value | Gross Unrealized Losses | ||||||||||||||||||||||||||||||||
| June 30, 2022 | ||||||||||||||||||||||||||||||||||||||
| Debt securities - available-for-sale: | ||||||||||||||||||||||||||||||||||||||
U.S. government and agency obligations | $ | 2,921 | $ | (152) | $ | 474 | $ | (57) | $ | 3,395 | $ | (209) | ||||||||||||||||||||||||||
| State and municipal obligations | 4,807 | (355) | 209 | (26) | 5,016 | (381) | ||||||||||||||||||||||||||||||||
| Corporate obligations | 16,894 | (1,200) | 2,261 | (315) | 19,155 | (1,515) | ||||||||||||||||||||||||||||||||
| U.S. agency mortgage-backed securities | 4,323 | (356) | 1,201 | (181) | 5,524 | (537) | ||||||||||||||||||||||||||||||||
Non-U.S. agency mortgage-backed securities | 2,354 | (151) | 354 | (50) | 2,708 | (201) | ||||||||||||||||||||||||||||||||
| Total debt securities - available-for-sale | $ | 31,299 | $ | (2,214) | $ | 4,499 | $ | (629) | $ | 35,798 | $ | (2,843) | ||||||||||||||||||||||||||
| December 31, 2021 | ||||||||||||||||||||||||||||||||||||||
| Debt securities - available-for-sale: | ||||||||||||||||||||||||||||||||||||||
U.S. government and agency obligations | $ | 1,976 | $ | (18) | $ | 249 | $ | (13) | $ | 2,225 | $ | (31) | ||||||||||||||||||||||||||
| State and municipal obligations | 1,386 | (19) | 31 | (1) | 1,417 | (20) | ||||||||||||||||||||||||||||||||
| Corporate obligations | 9,357 | (130) | 376 | (15) | 9,733 | (145) | ||||||||||||||||||||||||||||||||
| U.S. agency mortgage-backed securities | 3,078 | (52) | 116 | (3) | 3,194 | (55) | ||||||||||||||||||||||||||||||||
Non-U.S. agency mortgage-backed securities | 1,321 | (18) | 114 | (5) | 1,435 | (23) | ||||||||||||||||||||||||||||||||
| Total debt securities - available-for-sale | $ | 17,118 | $ | (237) | $ | 886 | $ | (37) | $ | 18,004 | $ | (274) | ||||||||||||||||||||||||||
The Company’s unrealized losses from debt securities as of June 30, 2022 were generated from approximately 33,000 positions out of a total of 40,000 positions. The Company believes that it will collect the timely principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities that impacted the Company’s assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers noting no significant credit deterioration since purchase. As of June 30, 2022, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities at June 30, 2022 and December 31, 2021 was not material.
9
3. Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2021 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
| (in millions) | Quoted Prices in Active Markets (Level 1) | Other Observable Inputs (Level 2) | Unobservable Inputs (Level 3) | Total Fair and Carrying Value | ||||||||||||||||||||||
| June 30, 2022 | ||||||||||||||||||||||||||
| Cash and cash equivalents | $ | 24,546 | $ | 66 | $ | — | $ | 24,612 | ||||||||||||||||||
| Debt securities - available-for-sale: | ||||||||||||||||||||||||||
| U.S. government and agency obligations | 3,432 | 168 | — | 3,600 | ||||||||||||||||||||||
| State and municipal obligations | — | 7,369 | — | 7,369 | ||||||||||||||||||||||
| Corporate obligations | 35 | 20,342 | 193 | 20,570 | ||||||||||||||||||||||
| U.S. agency mortgage-backed securities | — | 5,740 | — | 5,740 | ||||||||||||||||||||||
| Non-U.S. agency mortgage-backed securities | — | 2,725 | — | 2,725 | ||||||||||||||||||||||
| Total debt securities - available-for-sale | 3,467 | 36,344 | 193 | 40,004 | ||||||||||||||||||||||
| Equity securities | 1,894 | 18 | 68 | 1,980 | ||||||||||||||||||||||
| Assets under management | 1,655 | 2,268 | 94 | 4,017 | ||||||||||||||||||||||
| Total assets at fair value | $ | 31,562 | $ | 38,696 | $ | 355 | $ | 70,613 | ||||||||||||||||||
| Percentage of total assets at fair value | 45 | % | 54 | % | 1 | % | 100 | % | ||||||||||||||||||
| December 31, 2021 | ||||||||||||||||||||||||||
| Cash and cash equivalents | $ | 21,359 | $ | 16 | $ | — | $ | 21,375 | ||||||||||||||||||
| Debt securities - available-for-sale: | ||||||||||||||||||||||||||
| U.S. government and agency obligations | 3,017 | 181 | — | 3,198 | ||||||||||||||||||||||
| State and municipal obligations | — | 7,106 | — | 7,106 | ||||||||||||||||||||||
| Corporate obligations | 40 | 20,916 | 218 | 21,174 | ||||||||||||||||||||||
| U.S. agency mortgage-backed securities | — | 5,901 | — | 5,901 | ||||||||||||||||||||||
| Non-U.S. agency mortgage-backed securities | — | 2,838 | — | 2,838 | ||||||||||||||||||||||
| Total debt securities - available-for-sale | 3,057 | 36,942 | 218 | 40,217 | ||||||||||||||||||||||
| Equity securities | 2,090 | 23 | 64 | 2,177 | ||||||||||||||||||||||
| Assets under management | 1,972 | 2,376 | 101 | 4,449 | ||||||||||||||||||||||
| Total assets at fair value | $ | 28,478 | $ | 39,357 | $ | 383 | $ | 68,218 | ||||||||||||||||||
| Percentage of total assets at fair value | 42 | % | 57 | % | 1 | % | 100 | % | ||||||||||||||||||
There were no transfers in or out of Level 3 financial assets or liabilities during the six months ended June 30, 2022 or 2021.
10
The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
| (in millions) | Quoted Prices in Active Markets (Level 1) | Other Observable Inputs (Level 2) | Unobservable Inputs (Level 3) | Total Fair Value | Total Carrying Value | |||||||||||||||||||||||||||
| June 30, 2022 | ||||||||||||||||||||||||||||||||
| Debt securities - held-to-maturity | $ | 597 | $ | 104 | $ | — | $ | 701 | $ | 714 | ||||||||||||||||||||||
| Long-term debt and other financing obligations | $ | — | $ | 48,549 | $ | — | $ | 48,549 | $ | 50,041 | ||||||||||||||||||||||
| December 31, 2021 | ||||||||||||||||||||||||||||||||
| Debt securities - held-to-maturity | $ | 534 | $ | 102 | $ | 7 | $ | 643 | $ | 641 | ||||||||||||||||||||||
| Long-term debt and other financing obligations | $ | — | $ | 52,583 | $ | — | $ | 52,583 | $ | 46,003 | ||||||||||||||||||||||
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded during either the six months ended June 30, 2022 or 2021.
4. Medical Costs Payable
The following table shows the components of the change in medical costs payable for the six months ended June 30:
| (in millions) | 2022 | 2021 | ||||||||||||
| Medical costs payable, beginning of period | $ | 24,483 | $ | 21,872 | ||||||||||
| Acquisitions | 171 | 46 | ||||||||||||
| Reported medical costs: | ||||||||||||||
| Current year | 104,936 | 92,570 | ||||||||||||
| Prior years | (320) | (1,120) | ||||||||||||
| Total reported medical costs | 104,616 | 91,450 | ||||||||||||
| Medical payments: | ||||||||||||||
Payments for current year | (78,937) | (69,808) | ||||||||||||
| Payments for prior years | (21,355) | (18,429) | ||||||||||||
| Total medical payments | (100,292) | (88,237) | ||||||||||||
| Medical costs payable, end of period | $ | 28,978 | $ | 25,131 | ||||||||||
For the six months ended June 30, 2022, prior years’ medical cost reserve development included no individual factors that were significant. For the six months ended June 30, 2021, prior years’ medical cost reserve development was primarily driven by lower than expected health system utilization and the uncertainty of care patterns due to the disruption of the health care system caused by COVID-19. Medical costs payable included reserves for claims incurred by insured customers but not yet reported to the Company of $20.3 billion and $17.1 billion at June 30, 2022 and December 31, 2021, respectively.
5. Short-Term Borrowings and Long-Term Debt
In May 2022, the Company issued $6.0 billion of senior unsecured notes consisting of the following:
| (in millions, except percentages) | Par Value | |||||||
3.700% notes due May 2027 | $ | 600 | ||||||
4.000% notes due May 2029 | 900 | |||||||
4.200% notes due May 2032 | 1,500 | |||||||
4.750% notes due May 2052 | 2,000 | |||||||
4.950% notes due May 2062 | 1,000 | |||||||
11
For more information on the Company’s short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2021 10-K.
6. Dividends
In June 2022, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual rate of $6.60 compared to $5.80 per share, which the Company had paid since June 2021. Declaration and payment of future quarterly dividends is at the discretion of the Board of Directors and may be adjusted as business needs or market conditions change.
The following table provides details of the Company’s 2022 dividend payments:
| Payment Date | Amount per Share | Total Amount Paid | ||||||||||||
| (in millions) | ||||||||||||||
| March 22 | $ | 1.45 | $ | 1,363 | ||||||||||
| June 28 | 1.65 | 1,545 | ||||||||||||
7. Commitments and Contingencies
Pending Business Combinations
As of June 30, 2022, the Company has entered into agreements to acquire companies in the health care sector, most notably Change Healthcare (NASDAQ: CHNG) and LHC Group, Inc (NASDAQ: LHCG), subject to regulatory approval and other customary closing conditions. The total anticipated capital required for these business combinations, excluding associated disposition proceeds and the payoff of acquired indebtedness, is approximately $14 billion.
Legal Matters
Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may be incurred.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office for Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the DOJ, the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Consumer Financial Protection Bureau (CFPB), the Defense Contract Audit Agency and other governmental authorities. Similarly, our international businesses are also subject to investigations, audits and reviews by applicable foreign governments, including South American and other non-U.S. governmental authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans.
On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges that the Company made improper Medicare risk adjustment submissions and violated the False Claims Act. On
12
February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, the DOJ moved to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without prejudice. The Company cannot reasonably estimate the outcome that may result from this matter given its procedural status.
8. Business Combinations
During the six months ended June 30, 2022, the Company completed several business combinations for total consideration of $8.1 billion.
Acquired assets (liabilities) at acquisition date were:
The majority of goodwill is not deductible for income tax purposes. The preliminary purchase price allocations for the various business combinations are subject to adjustment as valuation analyses, primarily related to intangible assets and contingent liabilities, are finalized.
The acquisition date fair values and weighted-average useful lives assigned to finite-lived intangible assets were:
| (in millions, except years) | Fair Value | Weighted-Average Useful Life | ||||||||||||
| Customer-related | $ | 915 | 9 years | |||||||||||
| Trademarks and technology | 800 | 9 years | ||||||||||||
| Other | 80 | 11 years | ||||||||||||
| Total acquired finite-lived intangible assets | $ | 1,795 | 9 years | |||||||||||
The results of operations and financial condition of acquired entities have been included in the Company’s consolidated results and the results of the corresponding operating segment as of the date of acquisition. Through June 30, 2022, acquired entities impact on revenues and net earnings was not material.
Unaudited pro forma revenues and net earnings for the six months ended June 30, 2022 and 2021 as if the business combinations had occurred on January 1, 2021 were immaterial for both periods.
9. Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more information on the Company’s segments, see Part I, Item I, “Business” and Note 13 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2021 10-K. Total assets at Optum Health and Optum Rx increased to $67.9 billion and $46.2 billion as of June 30, 2022 compared to $60.5 billion and $40.2 billion as of December 31, 2021, respectively. The increase in total assets at Optum Health and Optum Rx was primarily due to goodwill from business combinations of $4.5 billion and $3.8 billion, respectively.
13
On January 1, 2022, the Company realigned its operating segments to combine UnitedHealthcare Global and UnitedHealthcare Employer & Individual. The realignment had no impact on the Company’s reportable segments.
The following tables present reportable segment financial information:
| Optum | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | UnitedHealthcare | Optum Health | Optum Insight | Optum Rx | Optum Eliminations | Optum | Corporate and Eliminations | Consolidated | ||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended June 30, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Revenues - unaffiliated customers: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Premiums | $ | 59,368 | $ | 4,528 | $ | — | $ | — | $ | — | $ | 4,528 | $ | — | $ | 63,896 | ||||||||||||||||||||||||||||||||||
| Products | — | 6 | 58 | 9,432 | — | 9,496 | — | 9,496 | ||||||||||||||||||||||||||||||||||||||||||
| Services | 2,542 | 2,740 | 1,034 | 329 | — | 4,103 | — | 6,645 | ||||||||||||||||||||||||||||||||||||||||||
Total revenues - unaffiliated customers | 61,910 | 7,274 | 1,092 | 9,761 | — | 18,127 | — | 80,037 | ||||||||||||||||||||||||||||||||||||||||||
Total revenues - affiliated customers | — | 10,224 | 2,181 | 15,038 | (588) | 26,855 | (26,855) | — | ||||||||||||||||||||||||||||||||||||||||||
Investment and other income | 195 | 85 | 9 | 6 | — | 100 | — | 295 | ||||||||||||||||||||||||||||||||||||||||||
| Total revenues | $ | 62,105 | $ | 17,583 | $ | 3,282 | $ | 24,805 | $ | (588) | $ | 45,082 | $ | (26,855) | $ | 80,332 | ||||||||||||||||||||||||||||||||||
| Earnings from operations | $ | 3,850 | $ | 1,399 | $ | 839 | $ | 1,044 | $ | — | $ | 3,282 | $ | — | $ | 7,132 | ||||||||||||||||||||||||||||||||||
| Interest expense | — | — | — | — | — | — | (467) | (467) | ||||||||||||||||||||||||||||||||||||||||||
Earnings before income taxes | $ | 3,850 | $ | 1,399 | $ | 839 | $ | 1,044 | $ | — | $ | 3,282 | $ | (467) | $ | 6,665 | ||||||||||||||||||||||||||||||||||
| Three Months Ended June 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Revenues - unaffiliated customers: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Premiums | $ | 52,858 | $ | 3,375 | $ | — | $ | — | $ | — | $ | 3,375 | $ | — | $ | 56,233 | ||||||||||||||||||||||||||||||||||
| Products | — | 9 | 33 | 8,391 | — | 8,433 | — | 8,433 | ||||||||||||||||||||||||||||||||||||||||||
| Services | 2,440 | 2,461 | 930 | 268 | — | 3,659 | — | 6,099 | ||||||||||||||||||||||||||||||||||||||||||
Total revenues - unaffiliated customers | 55,298 | 5,845 | 963 | 8,659 | — | 15,467 | — | 70,765 | ||||||||||||||||||||||||||||||||||||||||||
Total revenues - affiliated customers | — | 7,221 | 1,921 | 13,792 | (478) | 22,456 | (22,456) | — | ||||||||||||||||||||||||||||||||||||||||||
Investment and other income | 176 | 234 | 73 | 73 | — | 380 | — | 556 | ||||||||||||||||||||||||||||||||||||||||||
| Total revenues | $ | 55,474 | $ | 13,300 | $ | 2,957 | $ | 22,524 | $ | (478) | $ | 38,303 | $ | (22,456) | $ | 71,321 | ||||||||||||||||||||||||||||||||||
| Earnings from operations | $ | 3,095 | $ | 1,128 | $ | 762 | $ | 993 | $ | — | $ | 2,883 | $ | — | $ | 5,978 | ||||||||||||||||||||||||||||||||||
| Interest expense | — | — | — | — | — | — | (410) | (410) | ||||||||||||||||||||||||||||||||||||||||||
Earnings before income taxes | $ | 3,095 | $ | 1,128 | $ | 762 | $ | 993 | $ | — | $ | 2,883 | $ | (410) | $ | 5,568 | ||||||||||||||||||||||||||||||||||
14
| Optum | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | UnitedHealthcare | Optum Health | Optum Insight | Optum Rx | Optum Eliminations | Optum | Corporate and Eliminations | Consolidated | ||||||||||||||||||||||||||||||||||||||||||
| Six Months Ended June 30, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Revenues - unaffiliated customers: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Premiums | $ | 119,305 | $ | 8,661 | $ | — | $ | — | $ | — | $ | 8,661 | $ | — | $ | 127,966 | ||||||||||||||||||||||||||||||||||
| Products | — | 12 | 98 | 18,726 | — | 18,836 | — | 18,836 | ||||||||||||||||||||||||||||||||||||||||||
| Services | 5,057 | 5,298 | 2,008 | 654 | — | 7,960 | — | 13,017 | ||||||||||||||||||||||||||||||||||||||||||
Total revenues - unaffiliated customers | 124,362 | 13,971 | 2,106 | 19,380 | — | 35,457 | — | 159,819 | ||||||||||||||||||||||||||||||||||||||||||
Total revenues - affiliated customers | — | 20,053 | 4,319 | 29,329 | (1,141) | 52,560 | (52,560) | — | ||||||||||||||||||||||||||||||||||||||||||
Investment and other income | 338 | 241 | 76 | 7 | — | 324 | — | 662 | ||||||||||||||||||||||||||||||||||||||||||
| Total revenues | $ | 124,700 | $ | 34,265 | $ | 6,501 | $ | 48,716 | $ | (1,141) | $ | 88,341 | $ | (52,560) | $ | 160,481 | ||||||||||||||||||||||||||||||||||
| Earnings from operations | $ | 7,648 | $ | 2,765 | $ | 1,686 | $ | 1,983 | $ | — | $ | 6,434 | $ | — | $ | 14,082 | ||||||||||||||||||||||||||||||||||
| Interest expense | — | — | — | — | — | — | (900) | (900) | ||||||||||||||||||||||||||||||||||||||||||
Earnings before income taxes | $ | 7,648 | $ | 2,765 | $ | 1,686 | $ | 1,983 | $ | — | $ | 6,434 | $ | (900) | $ | 13,182 | ||||||||||||||||||||||||||||||||||
| Six Months Ended June 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Revenues - unaffiliated customers: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Premiums | $ | 105,416 | $ | 6,303 | $ | — | $ | — | $ | — | $ | 6,303 | $ | — | $ | 111,719 | ||||||||||||||||||||||||||||||||||
| Products | — | 17 | 70 | 16,686 | — | 16,773 | — | 16,773 | ||||||||||||||||||||||||||||||||||||||||||
| Services | 4,790 | 4,797 | 1,891 | 539 | — | 7,227 | — | 12,017 | ||||||||||||||||||||||||||||||||||||||||||
Total revenues - unaffiliated customers | 110,206 | 11,117 | 1,961 | 17,225 | — | 30,303 | — | 140,509 | ||||||||||||||||||||||||||||||||||||||||||
Total revenues - affiliated customers | — | 14,173 | 3,742 | 26,796 | (953) | 43,758 | (43,758) | — | ||||||||||||||||||||||||||||||||||||||||||
Investment and other income | 382 | 413 | 106 | 107 | — | 626 | — | 1,008 | ||||||||||||||||||||||||||||||||||||||||||
| Total revenues | $ | 110,588 | $ | 25,703 | $ | 5,809 | $ | 44,128 | $ | (953) | $ | 74,687 | $ | (43,758) | $ | 141,517 | ||||||||||||||||||||||||||||||||||
| Earnings from operations | $ | 7,203 | $ | 2,090 | $ | 1,541 | $ | 1,883 | $ | — | $ | 5,514 | $ | — | $ | 12,717 | ||||||||||||||||||||||||||||||||||
| Interest expense | — | — | — | — | — | — | (807) | (807) | ||||||||||||||||||||||||||||||||||||||||||
Earnings before income taxes | $ | 7,203 | $ | 2,090 | $ | 1,541 | $ | 1,883 | $ | — | $ | 5,514 | $ | (807) | $ | 11,910 | ||||||||||||||||||||||||||||||||||
15
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and Notes and with our 2021 10-K, including the Consolidated Financial Statements and Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in that report. Unless the context indicates otherwise, references to the terms “UnitedHealth Group,” the “Company,” “we,” “our” or “us” used throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2021 10-K and in the discussion below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group Incorporated is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary business platforms — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations we are privileged to serve.
We have four reportable segments across our two business platforms, Optum and UnitedHealthcare:
•Optum Health;
•Optum Insight;
•Optum Rx; and
•UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State.
Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2021 10-K and additional information on our segments, including the realignment of our UnitedHealthcare operating segments to combine UnitedHealthcare Global and UnitedHealthcare Employer and Individual, can be found in this Item 2 and in Note 9 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Business Trends
Our businesses participate in the United States, South America and certain other international health markets. Overall spending on health care is impacted by inflation, utilization, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being. The rate of market growth may be affected by a variety of factors, including macroeconomic conditions, such as the economic impact of COVID-19, and regulatory changes, which could impact our results of operations, including our continued efforts to control health care costs.
Pricing Trends. To price our health care benefit products, we start with our view of expected future costs, including any potential impacts from COVID-19. We frequently evaluate and adjust our approach in each of the local markets we serve, considering all relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations, including minimum medical loss ratio (MLR) thresholds and similar revenue adjustments. We will continue seeking to balance growth and profitability across all these dimensions.
The commercial risk market remains highly competitive in the small group, large group and individual segments. We expect broad-based competition to continue as the industry adapts to individual and employer needs.
Government programs in the community and senior sector tend to receive lower rates of increase than the commercial market due to governmental budget pressures and lower cost trends.
Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, health system utilization and prescription drug costs. COVID-19 related care and testing costs as well as the deferral of care have also impacted medical cost trends in the current year and may continue in future years. Future medical cost trends may be impacted by increased consumer
16
demand for care, and potentially even higher acuity care, due to the temporary deferral of care since the onset of the pandemic. We endeavor to mitigate those increases by engaging physicians and consumers with information and helping them make clinically sound choices, with the objective of helping them achieve high-quality, affordable care. The continued uncertain impact of COVID-19 may impact our ability to estimate medical costs payable, which has resulted in, and could result in, increased variability to medical cost reserve development.
COVID-19 Trends and Uncertainties
The COVID-19 pandemic continues to evolve and the ultimate impact on our business, results of operations, financial condition and cash flows remains uncertain. During the six months ended June 30, 2022, overall care was near normal baseline levels, with certain areas of care at or approaching seasonal baselines, and other areas below. COVID-19 treatment and testing costs continue to be mitigated by the temporary deferral of care, both generally varying with COVID-19 incidence rates. The relationship between COVID-19 care costs and non-COVID-19 utilization lagged in the second quarter, with increased non-COVID-19 utilization not as rapidly coinciding with decreased COVID-19 care and incidence rates as it had throughout the pandemic. In future periods, care patterns may moderately exceed normal baselines as previously deferred care is obtained. Though not yet experienced, acuity may temporarily rise due to missed regular care.
COVID-19 may continue to influence customer and consumer behavior, which could impact how and where care is delivered, benefit product designs, and the manner in which consumers wish to receive their prescription drugs or infusion services. Disrupted care patterns, as a result of the pandemic, have affected and may continue to temporarily affect the ability to obtain complete member health status information, impacting revenue in businesses utilizing risk adjustment methodologies.
The ultimate overall impact is uncertain and dependent on the future pacing, intensity and duration of the pandemic, the severity of new variants of the COVID-19 virus, the effectiveness and extent of administration of vaccination and treatments and general economic uncertainty.
SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select second quarter 2022 year-over-year operating comparisons to second quarter 2021 and other financial results.
•Consolidated revenues grew 13%, UnitedHealthcare revenues grew 12% and Optum revenues grew 18%.
•UnitedHealthcare served 1.6 million more people, led by growth in community and senior programs.
•Consolidated earnings from operations of $7.1 billion compared to $6.0 billion last year, included growth of 24% at UnitedHealthcare and 14% at Optum.
•Diluted earnings per common share were $5.34.
•Cash flows from operations for the six months ended June 30, 2022 were $12.2 billion.
•Return on equity was 27.9%.
17
RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
| (in millions, except percentages and per share data) | Three Months Ended June 30, | Increase/ (Decrease) | Six Months Ended June 30, | Increase/(Decrease) | ||||||||||||||||||||||||||||||||||||||||||||||
| 2022 | 2021 | 2022 vs. 2021 | 2022 | 2021 | 2022 vs. 2021 | |||||||||||||||||||||||||||||||||||||||||||||
| Revenues: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Premiums | $ | 63,896 | $ | 56,233 | $ | 7,663 | 14 | % | $ | 127,966 | $ | 111,719 | $ | 16,247 | 15 | % | ||||||||||||||||||||||||||||||||||
| Products | 9,496 | 8,433 | 1,063 | 13 | 18,836 | 16,773 | 2,063 | 12 | ||||||||||||||||||||||||||||||||||||||||||
| Services | 6,645 | 6,099 | 546 | 9 | 13,017 | 12,017 | 1,000 | 8 | ||||||||||||||||||||||||||||||||||||||||||
| Investment and other income | 295 | 556 | (261) | (47) | 662 | 1,008 | (346) | (34) | ||||||||||||||||||||||||||||||||||||||||||
| Total revenues | 80,332 | 71,321 | 9,011 | 13 | 160,481 | 141,517 | 18,964 | 13 | ||||||||||||||||||||||||||||||||||||||||||
| Operating costs: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical costs | 52,093 | 46,546 | 5,547 | 12 | 104,616 | 91,450 | 13,166 | 14 | ||||||||||||||||||||||||||||||||||||||||||
| Operating costs | 11,709 | 10,359 | 1,350 | 13 | 23,110 | 20,582 | 2,528 | 12 | ||||||||||||||||||||||||||||||||||||||||||
| Cost of products sold | 8,596 | 7,660 | 936 | 12 | 17,083 | 15,232 | 1,851 | 12 | ||||||||||||||||||||||||||||||||||||||||||
| Depreciation and amortization | 802 | 778 | 24 | 3 | 1,590 | 1,536 | 54 | 4 | ||||||||||||||||||||||||||||||||||||||||||
| Total operating costs | 73,200 | 65,343 | 7,857 | 12 | 146,399 | 128,800 | 17,599 | 14 | ||||||||||||||||||||||||||||||||||||||||||
| Earnings from operations | 7,132 | 5,978 | 1,154 | 19 | 14,082 | 12,717 | 1,365 | 11 | ||||||||||||||||||||||||||||||||||||||||||
| Interest expense | (467) | (410) | (57) | 14 | (900) | (807) | (93) | 12 | ||||||||||||||||||||||||||||||||||||||||||
| Earnings before income taxes | 6,665 | 5,568 | 1,097 | 20 | 13,182 | 11,910 | 1,272 | 11 | ||||||||||||||||||||||||||||||||||||||||||
| Provision for income taxes | (1,466) | (1,196) | (270) | 23 | (2,835) | (2,560) | (275) | 11 | ||||||||||||||||||||||||||||||||||||||||||
| Net earnings | 5,199 | 4,372 | 827 | 19 | 10,347 | 9,350 | 997 | 11 | ||||||||||||||||||||||||||||||||||||||||||
| Earnings attributable to noncontrolling interests | (129) | (106) | (23) | 22 | (250) | (222) | (28) | 13 | ||||||||||||||||||||||||||||||||||||||||||
| Net earnings attributable to UnitedHealth Group common shareholders | $ | 5,070 | $ | 4,266 | $ | 804 | 19 | % | $ | 10,097 | $ | 9,128 | $ | 969 | 11 | % | ||||||||||||||||||||||||||||||||||
| Diluted earnings per share attributable to UnitedHealth Group common shareholders | $ | 5.34 | $ | 4.46 | $ | 0.88 | 20 | % | $ | 10.61 | $ | 9.55 | $ | 1.06 | 11 | % | ||||||||||||||||||||||||||||||||||
| Medical care ratio (a) | 81.5 | % | 82.8 | % | (1.3) | % | 81.8 | % | 81.9 | % | (0.1) | % | ||||||||||||||||||||||||||||||||||||||
| Operating cost ratio | 14.6 | 14.5 | 0.1 | 14.4 | 14.5 | (0.1) | ||||||||||||||||||||||||||||||||||||||||||||
| Operating margin | 8.9 | 8.4 | 0.5 | 8.8 | 9.0 | (0.2) | ||||||||||||||||||||||||||||||||||||||||||||
| Tax rate | 22.0 | 21.5 | 0.5 | 21.5 | 21.5 | — | ||||||||||||||||||||||||||||||||||||||||||||
| Net earnings margin (b) | 6.3 | 6.0 | 0.3 | 6.3 | 6.5 | (0.2) | ||||||||||||||||||||||||||||||||||||||||||||
| Return on equity (c) | 27.9 | % | 25.2 | % | 2.7 | % | 27.9 | % | 27.3 | % | 0.6 | % | ||||||||||||||||||||||||||||||||||||||
(a)Medical care ratio (MCR) is calculated as medical costs divided by premium revenue.
(b)Net earnings margin attributable to UnitedHealth Group shareholders.
(c)Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’ equity. Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year and the shareholders’ equity balances at the end of each of the quarters in the year presented.
2022 RESULTS OF OPERATIONS COMPARED TO 2021 RESULTS OF OPERATIONS
Consolidated Financial Results
Revenues
The increases in revenues were primarily driven by growth in the number of people served through Medicare Advantage, Medicaid and commercial offerings; pricing trends; and growth across the Optum businesses.
Medical Costs and MCR
Medical costs increased due to growth in people served through Medicare Advantage, Medicaid and commercial offerings. For the three months ended June 30, 2022, MCR decreased due to COVID-19 effects and business mix. For the six months ended June 30, 2022, MCR decreased as a result of COVID-19 effects offset by business mix and decreased prior years favorable development, primarily due to the effects of COVID-19 in 2021.
18
Operating Cost Ratio
For the three months ended June 30, 2022, the operating cost ratio increased primarily due to business mix and investments, partially offset by COVID-19 related revenue effects. For the six months ended June 30, 2022, the operating cost ratio decreased as a result of COVID-19 related revenue effects, partially offset by business mix.
Reportable Segments
See Note 9 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more information on our segments. We utilize various metrics to evaluate and manage our reportable segments, including people served by UnitedHealthcare by major market segment and funding arrangement, people served by Optum Health and adjusted scripts for Optum Rx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also allow management and investors to evaluate and understand business mix, including the mix of care delivered through value-based care models at Optum Health, level and scope of services provided to people and pricing trends when comparing the metrics to revenue by segment.
The following table presents a summary of the reportable segment financial information:
| Three Months Ended June 30, | Increase/(Decrease) | Six Months Ended June 30, | Increase/(Decrease) | |||||||||||||||||||||||||||||||||||||||||||||||
| (in millions, except percentages) | 2022 | 2021 | 2022 vs. 2021 | 2022 | 2021 | 2022 vs. 2021 | ||||||||||||||||||||||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||||||||||||||||||||||||||||
| UnitedHealthcare | $ | 62,105 | $ | 55,474 | $ | 6,631 | 12 | % | $ | 124,700 | $ | 110,588 | $ | 14,112 | 13 | % | ||||||||||||||||||||||||||||||||||
| Optum Health | 17,583 | 13,300 | 4,283 | 32 | 34,265 | 25,703 | 8,562 | 33 | ||||||||||||||||||||||||||||||||||||||||||
| Optum Insight | 3,282 | 2,957 | 325 | 11 | 6,501 | 5,809 | 692 | 12 | ||||||||||||||||||||||||||||||||||||||||||
| Optum Rx | 24,805 | 22,524 | 2,281 | 10 | 48,716 | 44,128 | 4,588 | 10 | ||||||||||||||||||||||||||||||||||||||||||
| Optum eliminations | (588) | (478) | (110) | 23 | (1,141) | (953) | (188) | 20 | ||||||||||||||||||||||||||||||||||||||||||
| Optum | 45,082 | 38,303 | 6,779 | 18 | 88,341 | 74,687 | 13,654 | 18 | ||||||||||||||||||||||||||||||||||||||||||
| Eliminations | (26,855) | (22,456) | (4,399) | 20 | (52,560) | (43,758) | (8,802) | 20 | ||||||||||||||||||||||||||||||||||||||||||
| Consolidated revenues | $ | 80,332 | $ | 71,321 | $ | 9,011 | 13 | % | $ | 160,481 | $ | 141,517 | $ | 18,964 | 13 | % | ||||||||||||||||||||||||||||||||||
| Earnings from operations | ||||||||||||||||||||||||||||||||||||||||||||||||||
| UnitedHealthcare | $ | 3,850 | $ | 3,095 | $ | 755 | 24 | % | $ | 7,648 | $ | 7,203 | $ | 445 | 6 | % | ||||||||||||||||||||||||||||||||||
| Optum Health | 1,399 | 1,128 | 271 | 24 | 2,765 | 2,090 | 675 | 32 | ||||||||||||||||||||||||||||||||||||||||||
| Optum Insight | 839 | 762 | 77 | 10 | 1,686 | 1,541 | 145 | 9 | ||||||||||||||||||||||||||||||||||||||||||
| Optum Rx | 1,044 | 993 | 51 | 5 | 1,983 | 1,883 | 100 | 5 | ||||||||||||||||||||||||||||||||||||||||||
| Optum | 3,282 | 2,883 | 399 | 14 | 6,434 | 5,514 | 920 | 17 | ||||||||||||||||||||||||||||||||||||||||||
| Consolidated earnings from operations | $ | 7,132 | $ | 5,978 | $ | 1,154 | 19 | % | $ | 14,082 | $ | 12,717 | $ | 1,365 | 11 | % | ||||||||||||||||||||||||||||||||||
| Operating margin | ||||||||||||||||||||||||||||||||||||||||||||||||||
| UnitedHealthcare | 6.2 | % | 5.6 | % | 0.6 | % | 6.1 | % | 6.5 | % | (0.4) | % | ||||||||||||||||||||||||||||||||||||||
| Optum Health | 8.0 | 8.5 | (0.5) | 8.1 | 8.1 | — | ||||||||||||||||||||||||||||||||||||||||||||
| Optum Insight | 25.6 | 25.8 | (0.2) | 25.9 | 26.5 | (0.6) | ||||||||||||||||||||||||||||||||||||||||||||
| Optum Rx | 4.2 | 4.4 | (0.2) | 4.1 | 4.3 | (0.2) | ||||||||||||||||||||||||||||||||||||||||||||
| Optum | 7.3 | 7.5 | (0.2) | 7.3 | 7.4 | (0.1) | ||||||||||||||||||||||||||||||||||||||||||||
| Consolidated operating margin | 8.9 | % | 8.4 | % | 0.5 | % | 8.8 | % | 9.0 | % | (0.2) | % | ||||||||||||||||||||||||||||||||||||||
19
UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
| Three Months Ended June 30, | Increase/(Decrease) | Six Months Ended June 30, | Increase/(Decrease) | |||||||||||||||||||||||||||||||||||||||||||||||
| (in millions, except percentages) | 2022 | 2021 | 2022 vs. 2021 | 2022 | 2021 | 2022 vs. 2021 | ||||||||||||||||||||||||||||||||||||||||||||
| UnitedHealthcare Employer & Individual - Domestic | $ | 15,567 | $ | 14,942 | $ | 625 | 4 | % | $ | 31,389 | $ | 29,574 | $ | 1,815 | 6 | % | ||||||||||||||||||||||||||||||||||
| UnitedHealthcare Employer & Individual - Global (a) | 2,247 | 2,118 | 129 | 6 | 4,380 | 4,153 | 227 | 5 | ||||||||||||||||||||||||||||||||||||||||||
| UnitedHealthcare Employer & Individual - Total (a) | 17,814 | 17,060 | 754 | 4 | 35,769 | 33,727 | 2,042 | 6 | ||||||||||||||||||||||||||||||||||||||||||
| UnitedHealthcare Medicare & Retirement | 28,625 | 25,304 | 3,321 | 13 | 57,725 | 50,778 | 6,947 | 14 | ||||||||||||||||||||||||||||||||||||||||||
| UnitedHealthcare Community & State | 15,666 | 13,110 | 2,556 | 19 | 31,206 | 26,083 | 5,123 | 20 | ||||||||||||||||||||||||||||||||||||||||||
| Total UnitedHealthcare revenues | $ | 62,105 | $ | 55,474 | $ | 6,631 | 12 | % | $ | 124,700 | $ | 110,588 | $ | 14,112 | 13 | % | ||||||||||||||||||||||||||||||||||
(a) On January 1, 2022, we realigned our operating segments to combine UnitedHealthcare Global and UnitedHealthcare Employer & Individual.
The following table summarizes the number of people served by our UnitedHealthcare businesses, by major market segment and funding arrangement:
Commercial business increased primarily due to organic growth and business combinations. Medicare Advantage increased due to growth in people served through individual and group Medicare Advantage plans. The increase in people served through Medicaid was primarily driven by states continuing to ease redetermination requirements due to COVID-19, new state-based awards and growth in people served through Dual Special Needs Plans.
UnitedHealthcare’s revenues increased due to growth in the number of individuals served through Medicare Advantage and Medicaid, including a greater mix of people with higher acuity needs, and an increase in the number of individuals served through commercial benefits. For the three months ended June 30, 2022, earnings from operations increased due growth in people served and COVID-19 effects. For the six months ended June 30, 2022, earnings from operations increased due to growth in people served and COVID-19 effects, partially offset by decreased prior years favorable development, primarily due to the effects of COVID-19 in 2021.
Optum
Total revenues and earnings from operations increased due to growth across the Optum businesses. The results by segment were as follows:
Optum Health
Revenues at Optum Health increased primarily due to organic growth in value-based care arrangements and business combinations. Earnings from operations increased due to organic growth in value-based care arrangements, cost management initiatives and COVID-19 effects. Optum Health served approximately 101 million people as of June 30, 2022 compared to 99 million people as of June 30, 2021.
20
Optum Insight
Revenues and earnings from operations at Optum Insight increased due to growth in managed services and technology, with managed services growth driven by higher payer volumes and new health system partnerships.
Optum Rx
Revenues and earnings from operations at Optum Rx increased due to higher script volumes from growth in people served, increased utilization and organic growth in pharmacy care services, including community-behavioral and specialty pharmacy. Earnings from operations also increased as a result of continued supply chain management initiatives. Optum Rx fulfilled 357 million and 342 million adjusted scripts in the second quarters of 2022 and 2021, respectively.
LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Summary of our Major Sources and Uses of Cash and Cash Equivalents
| Six Months Ended June 30, | Increase/(Decrease) | |||||||||||||||||||
| (in millions) | 2022 | 2021 | 2022 vs. 2021 | |||||||||||||||||
| Sources of cash: | ||||||||||||||||||||
| Cash provided by operating activities | $ | 12,190 | $ | 11,545 | $ | 645 | ||||||||||||||
| Issuances of short-term borrowings and long-term debt, net of repayments | 6,162 | 4,858 | 1,304 | |||||||||||||||||
| Proceeds from common stock issuances | 756 | 764 | (8) | |||||||||||||||||
| Customer funds administered | 5,786 | 2,395 | 3,391 | |||||||||||||||||
| Total sources of cash | 24,894 | 19,562 | ||||||||||||||||||
| Uses of cash: | ||||||||||||||||||||
| Common stock repurchases | (5,000) | (2,900) | (2,100) | |||||||||||||||||
| Cash paid for acquisitions, net of cash assumed | (7,150) | (4,642) | (2,508) | |||||||||||||||||
| Purchases of investments, net of sales and maturities | (3,366) | (2,789) | (577) | |||||||||||||||||
| Purchases of property, equipment and capitalized software | (1,212) | (1,130) | (82) | |||||||||||||||||
| Cash dividends paid | (2,908) | (2,548) | (360) | |||||||||||||||||
| Purchases of redeemable noncontrolling interests | (97) | (1,338) | 1,241 | |||||||||||||||||
| Other | (1,981) | (1,310) | (671) | |||||||||||||||||
| Total uses of cash | (21,714) | (16,657) | ||||||||||||||||||
| Effect of exchange rate changes on cash and cash equivalents | 57 | 6 | 51 | |||||||||||||||||
| Net increase in cash and cash equivalents | $ | 3,237 | $ | 2,911 | $ | 326 | ||||||||||||||
2022 Cash Flows Compared to 2021 Cash Flows
Increased cash flows provided by operating activities were primarily driven by increased net earnings partially offset by changes in working capital accounts. Other significant changes in sources or uses of cash year-over-year included increased customer funds administered, primarily driven by Medicare Part D timing, net issuances of short-term borrowings and long-term debt and decreased purchases of redeemable noncontrolling interests, partially offset by increased cash paid for acquisitions and share repurchases.
Financial Condition
As of June 30, 2022, our cash, cash equivalent, available-for-sale debt securities and equity securities balances of $68.0 billion included approximately $24.6 billion of cash and cash equivalents (of which $1.7 billion was available for general corporate use), $40.0 billion of debt securities and $3.4 billion of investments in equity securities. Given the significant portion of our portfolio held in cash and cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a material impact on our liquidity or capital position. Our available-for-sale debt securities portfolio had a weighted-average duration of 4.1 years and a weighted-average credit rating of “Double A” as of June 30, 2022. When multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average credit rating.
21
Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital resources and uses of liquidity are as follows:
Cash Requirements. A summary of our cash requirements as of December 31, 2021 was disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2021 10-K. During the six months ended June 30, 2022, there were no material changes to this previously disclosed information outside the ordinary course of business. We believe our capital resources are sufficient to meet future, short-term and long-term, liquidity needs. We continually evaluate opportunities to expand our operations, including through internal development of new products, programs and technology applications and business combinations.
Short-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing program, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2021 10-K.
Our revolving bank credit facilities contain various covenants, including covenants requiring us to maintain a defined debt to debt-plus-shareholders’ equity ratio of not more than 60%. As of June 30, 2022, our debt to debt-plus-shareholders’ equity ratio, as defined and calculated under the credit facilities, was approximately 37%.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, such as, to meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information on our long-term debt, see Note 5 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2021 10-K.
Credit Ratings. Our credit ratings as of June 30, 2022 were as follows:
| Moody’s | S&P Global | Fitch | A.M. Best | ||||||||||||||||||||||||||||||||||||||||||||
| Ratings | Outlook | Ratings | Outlook | Ratings | Outlook | Ratings | Outlook | ||||||||||||||||||||||||||||||||||||||||
| Senior unsecured debt | A3 | Positive | A+ | Stable | A | Stable | A | Stable | |||||||||||||||||||||||||||||||||||||||
| Commercial paper | P-2 | n/a | A-1 | n/a | F1 | n/a | AMB-1+ | n/a | |||||||||||||||||||||||||||||||||||||||
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase the cost of borrowing for us or limit our access to capital.
Share Repurchase Program. During the six months ended June 30, 2022, we repurchased approximately 10 million shares at an average price of $492.11 per share. As of June 30, 2022, we had Board of Directors’ authorization to purchase up to 35 million shares of our common stock.
Dividends. In June 2022, the Company’s Board of Directors increased our quarterly cash dividend to shareholders to an annual rate of $6.60 compared to $5.80 per share. For more information on our dividend, see Note 6 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Pending Business Combinations. As of June 30, 2022, we have entered into agreements to acquire companies in the health care sector, most notably Change Healthcare (NASDAQ: CHNG) and LHC Group, Inc. (NASDAQ: LHCG), subject to regulatory approval and other customary closing conditions. The total anticipated capital required for these business combinations, excluding associated disposition proceeds and the payoff of acquired indebtedness, is approximately $14 billion.
For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II, Item 7 in our 2021 10-K.
RECENTLY ISSUED ACCOUNTING STANDARDS
There are no recently issued accounting standards that are expected to have a material impact on our Condensed Consolidated Financial Statements.
22
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates, which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends. On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results, however, may materially differ from our calculated estimates, and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II, Item 7 in our 2021 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2021 10-K.
FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities law. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify forward-looking statements. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: risks associated with public health crises, large-scale medical emergencies and pandemics, such as the COVID-19 pandemic; our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or application; the DOJ’s legal action relating to the risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting revenue; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; failure to protect proprietary rights to our databases, software and related products; risks and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our ability to develop and deliver innovative products to health care payers and expand access to virtual care; changes in or challenges to our public sector contract awards; failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; failure to attract, develop, retain, and manage the succession of key employees and executives; the impact of potential changes in tax laws and regulations (including any increase in the U.S. income tax rate applicable to corporations); failure to achieve targeted operating cost productivity improvements; increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to manage successfully our strategic alliances or complete or receive anticipated benefits of strategic transactions; fluctuations in foreign currency exchange rates; downgrades in our credit ratings; our investment portfolio performance; impairment of our goodwill and intangible assets; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock. This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial condition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements, except as required by law.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in comprehensive income.
23
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June 30, 2022 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages):
| June 30, 2022 | ||||||||||||||||||||||||||
| Increase (Decrease) in Market Interest Rate | Investment Income Per Annum | Interest Expense Per Annum | Fair Value of Financial Assets | Fair Value of Financial Liabilities | ||||||||||||||||||||||
| 2 % | $ | 559 | $ | 215 | $ | (3,073) | $ | (7,035) | ||||||||||||||||||
| 1 | 280 | 107 | (1,583) | (3,824) | ||||||||||||||||||||||
| (1) | (248) | (107) | 1,666 | 4,595 | ||||||||||||||||||||||
| (2) | (248) | (191) | 3,380 | 10,165 | ||||||||||||||||||||||
Note: Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of June 30, 2022, the assumed hypothetical change in interest rates does not reflect the full 100 basis point reduction in interest income and the full 200 basis point reduction in interest income or interest expense, as the rates are assumed not to fall below zero. As of June 30, 2022, some of our investments had interest rates below 2% so the assumed hypothetical change in the fair value of investments does not reflect the full 200 basis point reduction.
ITEM 4. CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2022. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2022.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 7 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” of our 2021 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2021 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.
There have been no material changes to the risk factors as disclosed in our 2021 10-K.
24
ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities (a)
Second Quarter 2022
| For the Month Ended | Total Number of Shares Purchased | Average Price Paid Per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Number of Shares That May Yet Be Purchased Under The Plans or Programs | ||||||||||||||||||||||
| (in millions) | (in millions) | (in millions) | ||||||||||||||||||||||||
| April 30, 2022 | 1 | $ | 528.52 | 1 | 39 | |||||||||||||||||||||
| May 31, 2022 | 2 | 492.97 | 2 | 37 | ||||||||||||||||||||||
| June 30, 2022 | 2 | 480.23 | 2 | 35 | ||||||||||||||||||||||
| Total | 5 | $ | 499.30 | 5 | ||||||||||||||||||||||
(a) In November 1997, our Board of Directors adopted a share repurchase program, which the Board of Directors evaluates periodically. In June 2018, the Board of Directors renewed our share repurchase program with an authorization to repurchase up to 100 million shares of our common stock in open market purchases or other types of transactions (including prepaid or structured repurchase programs). There is no established expiration date for the program.
25
ITEM 6. EXHIBITS*
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the Securities Exchange Act of 1934 under Commission File No. 1-10864.
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |||||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | |||||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |||||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |||||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | |||||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101). | |||||||
________________
| * | Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request. | |||||||
26
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
UNITEDHEALTH GROUP INCORPORATED
/s/ ANDREW P. WITTY | Chief Executive Officer (principal executive officer) | Dated: | August 3, 2022 | |||||||||||
| Andrew P. Witty | ||||||||||||||
/s/ JOHN F. REX | Executive Vice President and Chief Financial Officer (principal financial officer) | Dated: | August 3, 2022 | |||||||||||
| John F. Rex | ||||||||||||||
/s/ THOMAS E. ROOS | Senior Vice President and Chief Accounting Officer (principal accounting officer) | Dated: | August 3, 2022 | |||||||||||
| Thomas E. Roos | ||||||||||||||
27